百奥赛图(02315)技术平台频结硕果 连签默克、Tubulis等推进国际化合作

智通财经
Sep 18

智通财经APP获悉,近日,百奥赛图(02315)公布与默克、Tubulis、IDEAYA的多项合作及研发进展引起市场关注,凸显其在抗体药物研发及创新递送技术领域的平台实力与国际合作成效。

近期,百奥赛图的合作伙伴IDEAYA Biosciences在十周年研发日上重点公布了双方共同推进的双特异性抗体偶联药物(bsADC)IDE034(BCG034)。该药物基于百奥赛图RenLite®平台开发,靶向B7-H3与PTK7,搭载公司新型Linker & Payload平台BLD1102,临床前数据显示其在特定肿瘤模型中疗效显著,尤其与PARG抑制剂IDE161联用呈现肿瘤特异性协同作用。IDEAYA计划于今年第四季度提交新药临床试验申请,适应症拟覆盖肺癌、结直肠癌等多个癌种。

此外,百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。Tubulis拟引进百奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。百奥赛图将获得一笔首付款,还将有权获得开发、监管及商业化里程碑付款以及个位数净销售额分成。与默克的合作则聚焦于推进开发应用于核酸药物的抗体偶联脂质递送解决方案,例如抗体偶联脂质纳米颗粒(LNP)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10